Evidence mapPaperPMID 40601247Full record

ReviewCellular oncology (Dordrecht, Netherlands)2025

Novel insights into lncRNAs as key regulators of post-translational modifications in cancer: mechanisms and therapeutic potential.

Yaqian Han, Shizhen Li, Linda Oyang, Shiwen Cui, Wenlong Zhang, Wenjuan Yang, Mingjing Peng, Shiming Tan, Longzheng Xia, Jinguan Lin and 8 more

Abstract readReview
In one paragraph

Review in Cellular oncology (Dordrecht, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. c-Medical sciences (Basel, Switzerland) · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yaqian Han *The Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Key Laboratory of Cancer Metabolism Changsha, Central South University, Hunan Cancer Hospital, 283 Tongzipo Road, Changsha, Changsha, Hunan, 410013, China.
Shizhen Li *The Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Key Laboratory of Cancer Metabolism Changsha, Central South University, Hunan Cancer Hospital, 283 Tongzipo Road, Changsha, Changsha, Hunan, 410013, China.
Linda Oyang *The Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Key Laboratory of Cancer Metabolism Changsha, Central South University, Hunan Cancer Hospital, 283 Tongzipo Road, Changsha, Changsha, Hunan, 410013, China.
Shiwen CuiThe Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Key Laboratory of Cancer Metabolism Changsha, Central South University, Hunan Cancer Hospital, 283 Tongzipo Road, Changsha, Changsha, Hunan, 410013, China.
Wenlong ZhangThe Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Key Laboratory of Cancer Metabolism Changsha, Central South University, Hunan Cancer Hospital, 283 Tongzipo Road, Changsha, Changsha, Hunan, 410013, China.
Wenjuan YangThe Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Key Laboratory of Cancer Metabolism Changsha, Central South University, Hunan Cancer Hospital, 283 Tongzipo Road, Changsha, Changsha, Hunan, 410013, China.
Mingjing PengThe Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Key Laboratory of Cancer Metabolism Changsha, Central South University, Hunan Cancer Hospital, 283 Tongzipo Road, Changsha, Changsha, Hunan, 410013, China.
Shiming TanThe Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Key Laboratory of Cancer Metabolism Changsha, Central South University, Hunan Cancer Hospital, 283 Tongzipo Road, Changsha, Changsha, Hunan, 410013, China.
Longzheng XiaThe Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Key Laboratory of Cancer Metabolism Changsha, Central South University, Hunan Cancer Hospital, 283 Tongzipo Road, Changsha, Changsha, Hunan, 410013, China.
Jinguan LinThe Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Key Laboratory of Cancer Metabolism Changsha, Central South University, Hunan Cancer Hospital, 283 Tongzipo Road, Changsha, Changsha, Hunan, 410013, China.
Xuemeng XuThe Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Key Laboratory of Cancer Metabolism Changsha, Central South University, Hunan Cancer Hospital, 283 Tongzipo Road, Changsha, Changsha, Hunan, 410013, China.
Nayiyuan WuThe Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Key Laboratory of Cancer Metabolism Changsha, Central South University, Hunan Cancer Hospital, 283 Tongzipo Road, Changsha, Changsha, Hunan, 410013, China.
Xianjie JiangThe Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Key Laboratory of Cancer Metabolism Changsha, Central South University, Hunan Cancer Hospital, 283 Tongzipo Road, Changsha, Changsha, Hunan, 410013, China.
Qiu PengThe Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Key Laboratory of Cancer Metabolism Changsha, Central South University, Hunan Cancer Hospital, 283 Tongzipo Road, Changsha, Changsha, Hunan, 410013, China.
Yanyan TangThe Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Key Laboratory of Cancer Metabolism Changsha, Central South University, Hunan Cancer Hospital, 283 Tongzipo Road, Changsha, Changsha, Hunan, 410013, China.
Xia LuoThe Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Key Laboratory of Cancer Metabolism Changsha, Central South University, Hunan Cancer Hospital, 283 Tongzipo Road, Changsha, Changsha, Hunan, 410013, China.
Qianjin LiaoDepartment of Oncology, Hunan Provincial People's Hospital (The First- Affiliated Hospital of Hunan Normal University), 61 Jiefang West Road, Changsha, Hunan, 410005, China. march-on@126.com.
Yujuan ZhouThe Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Key Laboratory of Cancer Metabolism Changsha, Central South University, Hunan Cancer Hospital, 283 Tongzipo Road, Changsha, Changsha, Hunan, 410013, China. zhouyujuan@hnca.org.cn.

Funding

National Natural Science Foundation of China 82173142
6 · The paper itself

Abstract

Abnormal post-translational modifications (PTMs) play a crucial role in tumor initiation and progression. However, the mechanisms by which lncRNAs, as emerging epigenetic regulators, mediate PTMs remain largely unexplored. This review provides a comprehensive summary of the latest research on the interplay between lncRNA-mediated PTMs and tumorigenesis. We delve into the molecular mechanisms underlying these interactions, focusing on how lncRNAs regulate PTMs to influence tumor progression. We place particular emphasis on the lncRNA-mediated PTMs as a driver of therapeutic resistance, shedding light on its potential as a novel target for cancer intervention. Furthermore, we highlight the therapeutic potential of targeting lncRNA-PTM networks, emphasizing novel RNA-based strategies and their clinical relevance in cancer treatment. We believe that an in-depth understanding of lncRNA-mediated PTMs could uncover novel therapeutic targets, paving the way for innovative approaches in cancer diagnosis and treatment.

Indexed as

NeoplasmsProtein Processing, Post-TranslationalRNA, Long NoncodingAnimalsHumansOligonucleotides, AntisenseOligonucleotides, AntisenseRNA, Long NoncodingCancerlncRNAsncRNAsPTMsTherapeutic tolerance

Identifiers

PMID40601247
PMCPMC12528201

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.